Early Abortion in Ontario: Options and Costs

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 2, 2006, Pages 142-148

  Limacher, James J ^a   Daniel, Imtiaz ^a   Isaacksz, Shiran ^a   Payne, Gregory J ^a   Dunn, Sheila ^b   Coyte, Peter C ^a   Laporte, Audrey ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abortion; Medical abortion; Methotrexate; Mifepristone; Misoprostol; Surgical abortion

Indexed keywords

METHOTREXATE; MIFEPRISTONE; ABORTIVE AGENT;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HOSPITAL COST; MEDICAL ABORTION; ONTARIO; SURGICAL ABORTION; VACUUM ASPIRATION; CANADA; CURETTAGE; ECONOMICS; FEMALE; HUMAN; INDUCED ABORTION; METHODOLOGY; OUTPATIENT DEPARTMENT; PREGNANCY;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; AMBULATORY CARE FACILITIES; FEMALE; HUMANS; METHOTREXATE; MIFEPRISTONE; ONTARIO; OUTPATIENT CLINICS, HOSPITAL; PREGNANCY; VACUUM CURETTAGE;

EID: 33745877163     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32065-5     Document Type: Article

References (39)

1. Bygdeman M., Danielsson K.G. Options for early therapeutic abortion: a comparative review. Drugs 2002, 62(17):2459-2470.
2. Kulier R., Fekih A., Hofmeyr G.J., Campana A. Surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev 2001, 4. CD002900.
3. Christin-Maitre S., Bouchard P., Spitz I.M. Medical termination of pregnancy. N Engl J Med 2000, 342(13):946-956.
4. Wiebe E., Dunn S., Guilbert E., Jacot F., Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol 2002, 99(5 Pt 1):813-819.
5. Creinin M.D., Darney P.D. Methotrexate and misoprostol for early abortion. Contraception 1993, 48(4):339-348.
6. Baird D.T., Blanchard K., Winikoff B., Coyaji K., Nguyen T.N., Ellertson C. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol 2002, 16(2):221-236.
7. Hepburn S. Complications of induced abortion. Fam Plann Inf Serv 1981, 1(6):21-28.
8. Hakim-Elahi E., Tovell H.M., Burnhill M.S. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990, 76(1):129-135.
9. Ulmann A., Silvestre L., Chemama L., Rezvani Y., Renault M., Aguillaume C.J., et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet Gynecol Scand 1992, 71(4):278-283.
10. Hausknecht R.U. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995, 333(9):537-540.
11. Wiebe E.R. Abortion induced with methotrexate and misoprostol. CMAJ 1996, 154(2):165-170.
12. Ashok P.W., Penney G.C., Flett G.M., Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998, 13(10):2962-2965.
13. Spitz I.M., Bardin C.W., Benton L., Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998, 338(18):1241-1247.
14. Creinin M.D. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception 2000, 62(3):117-124.
15. Kruse B., Poppema S., Creinin M.D., Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol 2000, 183(2 Suppl):S65-S75.
16. Schaff E.A., Fielding S.L., Westhoff C., Ellertson C., Eisinger S.H., Stadalius L.S., et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA 2000, 284(15):1948-1953.
17. Beadling W.V., Cook L., Henry J.B. Immunohematology. Clinical Diagnosis and Management by Laboratory Methods 2001, 660-717. W. B. Saunders, Philadelphia. 20th ed. J.B. Henry (Ed.).
18. Child T.J., Thomas J., Rees M., MacKenzie I.Z. Morbidity of first trimester aspiration termination and the seniority of the surgeon. Hum Reprod 2001, 16(5):875-878.
19. Ashok P.W., Templeton A., Wagaarachchi P.T., Flett G.M. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br J Obstet Gynaecol 2002, 109(11):1281-1289.
20. Paul M.E., Mitchell C.M., Rogers A.J., Fox M.C., Lackie E.G. Early surgical abortion: efficacy and safety. Am J Obstet Gynecol 2002, 187(2):407-411.
21. Say L., Kulier R., Gulmezoglu M., Campana A. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev 2002, 4. CD003037.
22. Creinin M.D., Potter C., Holovanisin M., Janczukiewicz L., Pymar H.C., Schwartz J.L., et al. Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. Am J Obstet Gynecol 2003, 188(3):664-669.
23. Keder L.M. Best practices in surgical abortion. Am J Obstet Gynecol 2003, 189(2):418-422.
24. Newhall E.P., Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000, 183(2 Suppl):S44-S53.
25. Pymar H.C., Creinin M.D. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gynecol 2000, 183(2 Suppl):S54-S64.
26. Murthy A., Creinin M.D. Pharmacoeconomics of medical abortion: a review of cost in the United States. Europe and Asia. Expert Opin Pharmacother 2003, 4(4):503-513.
27. British National Formulary 2003, British Medical Association and Royal Pharmaceutical Society of Great Britain, London.
28. Wiebe E.R., Janssen P. Time lost from work among women choosing medical or surgical abortions. Womens Health Issues 2000, 10(6):327-332.
29. Blanchard K., Winikoff B., Ellertson C. Misoprostol used alone for the termination of early pregnancy. A review of the evidence. Contraception 1999, 59(4):209-217.
30. Blanchard K., Winikoff B., Coyaji K., Nguyen T.N. Misoprostol alone-a new method of medical abortion?. J Am Med Womens Assoc 2000, 55(3 Suppl):189-190.
31. Carbonell J.L., Varela L., Velazco A., Fernandez C. The use of misoprostol for termination of early pregnancy. Contraception 1997, 55(3):165-168.
32. Carbonell J.L., Varela L., Velazco A., Tanda R., Barambio S., Chami S. Vaginal misoprostol 600 microg for early abortion. Eur J Contracept Reprod Health Care 2000, 5(1):46-51.
33. Creinin M.D., Shore E., Balasubramanian S., Harwood B. The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion. Contraception 2005, 71(1):26-30.
34. Henshaw R.C., Naji S.A., Russell I.T., Templeton A.A. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 1993, 307(6906):714-717.
35. Harvey S.M., Beckman L.J., Satre S.J. Choice of and satisfaction with methods of medical and surgical abortion among U.S. clinic patients. Fam Plann Perspect 2001, 33(5):212-216.
36. Wiebe E.R. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Contraception 1997, 55(2):67-71.
37. Slade P., Heke S., Fletcher J., Stewart P. A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care. Br J Obstet Gynaecol 1998, 105(12):1288-1295.
38. Urquhart D.R., Templeton A.A. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. Br J Obstet Gynaecol 1991, 98(4):396-399.
39. Iron K., Ferris L. Induced abortion 2002 February, 2002. Ontario Women's Health Council, Toronto.